Since ketone bodies (KBs) can trigger repair mechanisms in response to inflammation, we specifically evaluated whether systemic ketosis <i>in vivo</i> can reduce CCR2 and AAA progression. This evidence concerns the gene CCR2 and triple-A syndrome.